廖崇任

廖崇任  助研究員
生技與藥物研究所
Email: tjliao@nhri.edu.tw

 


 
學歷

  • 美國馬里蘭大學大學公園市分校生物物理博士 (2014-2021)
  • 國立台灣大學應用物理碩士 (2010-2012)
  • 國立清華大學物理學士 (2005-2009)

經歷

  • 國家衛生研究院生技與藥物研究所 助研究員 (2026-至今)
  • 美國國家衛生研究院轉化科學促進中心 博士後研究員 (2022-2025)
  • 美國食品藥品監督管理局國家毒理學研究中心 博士後研究員 (2020-2022)
  • 美國國家衛生研究院國家癌症研究所 研究生學者 (2015-2020)

研究興趣

生物物理、生物化學、生物資訊

榮譽與獎項

  • Translational Science Interagency Fellowship, NCATS, NIH (2022-2025)
  • Outstanding Graduate Assistant Award, UMD (2018)
  • Outstanding Poster in Structural Biology and Chemistry, Fort Detrick (2018)
  • Cancer Research Training Award Fellowship, NCI, NIH (2017-2020)
  • 教育部留學獎學金 (2017-2019)
  • Dean’s Fellowship, UMD (2014, 2017)

論文發表

  1. TJ. Liao, M. Xia, D. Tao, Y. Qu, B. Ning, J. Rule, W. Lee, R. Huang, J. Rakela, M. Chen: Identification of genetic risk factors associated with herbal and dietary supplement–induced acute liver failure using whole exome sequencing analysis, Gastro Hep Advance, 2025, 100716
  2. TJ. Liao, M. Xia, P. Hayashi, B. Pan, G. Aithal, M. Lucena, R. Andrade, J. Rule, W. Lee, J. Rakela, R. Huang, M. Chen: Genetic variants of GBP4: reduced risks for drug-induced acute liver failure, Liver International, 2025, 45 (2), e70011
  3. TJ. Liao, L. Crosby, K. Cross, G. Halford, M. Chen, R. Elespuru: Medical device report analyses from MAUDE: Device and patient outcomes, adverse events, and sex-based differential effects. Regulatory Toxicology and Pharmacology, 2024, 149, 105591
  4. A. Olubamiwa, TJ. Liao, J. Zhao, P. Dehanne, C. Noban, Y. Angin, O. Barberan, M. Chen: Drug interaction with UDP-glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury, Hepatology, 2024, 10.1097
  5. TJ. Liao, B. Pan, H. Hong, P. H. Hayashi, J. A. Rule, D. Ganger, W. M. Lee, J. Rakela, M. Chen: Whole exome sequencing reveals genetic variants in HLA class II genes associated with transplant-free survival of indeterminate acute liver failure. Clin. Transl. Gastroenterol., 2022, 10, 14309
  6. R. Moore, K. Ashby, TJ. Liao, M. Chen: Machine Learning to Identify Interaction of Single-Nucleotide Polymorphisms as a Risk Factor for Chronic Drug-Induced Liver Injury. Int. J. Environ. Res. Public Health, 2021, 18(20), 10603
  7. TJ. Liao, H. Jang, D. Fushman, R. Nussinov: SOS1 interacts with Grb2 through regions that induce closed nSH3 conformations. J. Chem. Phys., 2020, 153(4), 045106
  8. TJ. Liao, H. Jang, R. Nussinov, D. Fushman: High-affinity Interactions of the nSH3/cSH3 Domains of Grb2 with the C-terminal Proline-rich Domain of SOS1. J. Am. Chem. Soc., 2020, 142 (7), 3401-3411
  9. R. Nussinov, M. Zhang, CJ. Tsai, TJ. Liao, D. Fushman, H. Jang: Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: A comprehensive review underscoring the challenges in pharmacological intervention. Biophysical reviews, 2018, 1-20
  10. TJ. Liao, H. Jang, D. Fushman, R. Nussinov: Allosteric KRas4B can modulate SOS1 fast and slow activation cycles. Biophysical Journal, 2018, 115 (4), 629-641
  11. TJ. Liao, H. Jang, CJ. Tsai, D. Fushman, R. Nussinov: The dynamics mechanism of RASSF5 and MST kinase activation by Ras. Physical Chemistry Chemical Physics, 2017, 19, 6470-6480
  12. R. Nussinoc, H. Jang, CJ. Tsai, TJ. Liao, S. Li, D. Fushman & J. Zhang: Intrinsic protein disorder in oncogenic KRas signaling. Cellular and Molecular Life Science, 2017, 74(17):3245-3261
  13. TJ. Liao, CJ. Tsai, H. Jang, D. Fushman, R. Nussinoc: RASSF5: An MST activator and tumor suppressor in vivo but opposite in vitro. Current Opinion in Structural Biology, 2016, 41:217-224

Comments are closed.